Prandin (repaglinide)
- Region
- 🇪🇺 EU
- Active substance
- repaglinide
- Company
- Novo Nordisk A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- EU approval
- Mon 29 Jan 2001
- Application
- EMEA/H/C/000362
- ATC
- A10BX02
- Official record
- www.ema.europa.eu
Indication
Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Repaglinide Accord Withdrawn · Accord Healthcare S.L.U.
- 🇪🇺 Enyglid Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Repaglinide Krka Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Repaglinide Teva Authorised · Teva Pharma B.V.
- 🇪🇺 NovoNorm Authorised · Novo Nordisk A/S
- 🇪🇺 Repaglinide Sun Application withdrawn · Sun Pharmaceutical Industries B.V.
Follow Prandin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.